Table 4.
Multivariate analysis of NRM, relapse/progression, progression-free and overall survival after RIC or NMA allogeneic HCT for NHL
| N | Relative Risk (95% CI) | p-value* | Overall p-value | ||
|---|---|---|---|---|---|
| Non-relapse Mortality | |||||
| Age | |||||
| 40–54 | 614 | 0.0002 | |||
| 55–64 | 552 | 1.52 (1.24–1.86) | <.0001 | ||
| ≥ 65 | 82 | 1.57 (1.08–2.29) | 0.0189 | ||
| Significant covariates | |||||
| KPS | |||||
| ≥ 80 | 1064 | 0.0001 | |||
| < 80 | 114 | 1.87 (1.40–2.50) | <.0001 | ||
| NHL disease status | |||||
| CR1/CR2+ | 352 | <.0001 | |||
| PR1/PR2+ | 483 | 1.27 (0.99–1.63) | 0.0576 | ||
| Resistant disease | 306 | 1.90 (1.45–2.49) | <.0001 | ||
| HLA match | |||||
| HLA identical sibling | 499 | <.0001 | |||
| URD well matched | 495 | 1.36 (1.07–1.71) | 0.0116 | ||
| URD partially matched | 180 | 2.30 (1.74–3.03) | <.0001 | ||
| URD mismatched | 33 | 2.9 (1.76–4.77) | <.0001 | ||
| Relapse | |||||
| Age | |||||
| 40–54 | 614 | 0.059 | |||
| 55–64 | 552 | 1.29 (1.05–1.59) | 0.0176 | ||
| ≥ 65 | 82 | 1.18 (0.78–1.77) | 0.4321 | ||
| Significant covariates | |||||
| NHL disease status | |||||
| CR1/CR2+ | 352 | <.0001 | |||
| PR1/PR2+ | 483 | 1.67 (1.27–2.19) | 0.0002 | ||
| Resistant disease | 306 | 2.73 (2.04–3.64) | <.0001 | ||
| GVHD prophylaxis | |||||
| CSA+/−MTX+/−other | 386 | <.0001 | |||
| Tac+/−MTX+/−other | 376 | 0.88(0.67–1.16) | 0.3607 | ||
| T-cell depletion | 486 | 1.52 (1.18–1.95) | 0.0011 | ||
| Progression Free Survival | |||||
| Age | |||||
| 40–54 | 614 | 0.0001 | |||
| 55–64 | 552 | 1.37 (1.18–1.59) | <.0001 | ||
| ≥ 65 | 82 | 1.34 (1.01–1.76) | 0.0397 | ||
| Significant covariates | |||||
| KPS | |||||
| ≥ 80 | 1064 | <.0001 | |||
| < 80 | 114 | 1.63 (1.30–2.05) | <.0001 | ||
| NHL disease status | |||||
| CR1/CR2+ | 352 | <.0001 | |||
| PR1/PR2+ | 483 | 1.45 (1.21–1.75) | <.0001 | ||
| Resistant disease | 306 | 1.45 (1.88–2.78) | <.0001 | ||
| GVHD prophylaxis | |||||
| CSA+/−MTX+/−other | 386 | 0.0001 | |||
| Tac+/−MTX+/−other | 376 | 0.87 (0.72–1.06) | 0.1655 | ||
| T-cell depletion | 486 | 1.26 (1.05–1.50) | 0.0129 | ||
| HLA match | |||||
| HLA identical sibling | 499 | <.0001 | |||
| URD well matched | 495 | 1.13 (0.96–1.34) | 0.1468 | ||
| URD partially matched | 180 | 1.39 (1.12–1.72) | 0.0029 | ||
| URD mismatched | 33 | 2.28 (1.56–3.32) | <.0001 | ||
| Overall Survival | |||||
| Age | |||||
| 40–54 | 614 | <.0001 | |||
| 55–64 | 552 | 1.47 (1.25–1.72) | <.0001 | ||
| ≥ 65 | 82 | 1.47 (1.09–1.98) | 0.0127 | ||
| Significant covariates | |||||
| NHL disease status | |||||
| CR1/CR2+ | 352 | <.0001 | |||
| PR1/PR2+ | 483 | 1.29 (1.06–1.58) | 0.0113 | ||
| Resistant disease | 306 | 1.97 (1.60–2.44) | <.0001 | ||
| KPS | |||||
| ≥ 80 | 1064 | <.0001 | |||
| < 80 | 114 | 1.87 (1.48–2.37) | <.0001 | ||
| HLA match | |||||
| HLA identical sibling | 499 | <.0001 | |||
| URD well matched | 495 | 1.30 (1.09–1.56) | 0.0043 | ||
| URD partially matched | 180 | 1.90 (1.52–2.38) | <.0001 | ||
| URD mismatched | 33 | 2.21 (1.48–3.30) | 0.0001 | ||
| Conditioning Regimen | |||||
| Nonmyeloablative | 612 | 0.03 | |||
| Reduced Intensity | 636 | 1.19 (1.02–1.39) | 0.03 | ||
Abbreviations: KPS:Karnofsky performance status; CR:complete remission; PR:partial remission; HLA:human leukocyte antigen; URD:unrelated donor; GVHD:graft versus host disease; CSA:cyclosporine A; MTX:methotrexate; Tac:tacrolimus.
*
compared to reference group